Bli medlem
Bli medlem

Du är här

2016-05-17

Elekta: Leeds St James acquires eight Elekta linear accelerators for advanced cancer treatment

LEEDS, UK, May 17, 2016 - Leeds Cancer Centre, one of the largest
providers of cancer care in the UK, will upgrade its existing
treatment equipment with eight Elekta (EKTA-B.ST) Versa HD™
(https://www.elekta.com/versahd) linear accelerators. This
replacement will bring world-class treatment to the center, and
secure its leading position within cancer treatment in the country.

Dr. Viv Cosgrove, Head of Radiotherapy Physics at Leeds Cancer Centre,
says: "The new linear accelerators are able to deliver improvements
in treatment accuracy for patients. This will help us increase the
use of high dose radiation treatments such as stereotactic body
radiotherapy. These treatments reduce the total number of patient
visits whilst improving clinical effectiveness.

"The replacement of the existing equipment also allows us to create a
very advanced platform for increasing our research and innovation
programs, all of which directly benefit patients in the form of
clinical trials and research initiatives."

The Versa HD linear accelerators will include Agility™
(https://www.elekta.com/agility) multileaf collimators. These,
combined with VMAT delivery, could enable clinicians at Leeds Cancer
Centre to deliver complex head and neck plans up to 42 percent
faster.*

Paddy Greally, Elekta's Managing Director for the UK and Ireland,
says: "The UK registers more than 350,000 new cancer cases every
year, and half of these cancer patients will probably have
radiotherapy as part of their treatment plan. It is especially
satisfying for our colleagues in Crawley, where Versa HD linear
accelerators are produced, to know that we are helping to improve and
even save the lives of so many people."

The deal was facilitated by Medipass, a leading European managed
equipment services company, which partners with hospitals to manage
efficient medical equipment solutions.

Seven of the eight linear accelerators were booked during the fourth
quarter of Elekta's fiscal year 2015-16.

*As compared to previous generation Elekta digital linear
accelerators. Stieler F, Steil V, Wenz F, Lohr F, Department of
Radiation Oncology, University Medical Center Mannheim, University of
Heidelberg, Germany

# # #

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta
AB

Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time
Tobias Bülow, Director Financial Communication, Elekta AB
Tel: +46 722 215 017, e-mail: tobias.bulow@elekta.com
Time zone: CET: Central European Time
The above information is such that Elekta AB (publ) shall make public
in accordance with the Securities Market Act and/or the Financial
Instruments Trading Act. The information was published at 07:30 CET
on May 17, 2016.

About Elekta
Elekta is a human care company pioneering significant innovations and
clinical solutions for treating cancer and brain disorders. The
company develops sophisticated, state-of-the-art tools and treatment
planning systems for radiation therapy, radiosurgery and
brachytherapy, as well as workflow enhancing software systems across
the spectrum of cancer care. Stretching the boundaries of science and
technology, providing intelligent and resource-efficient solutions
that offer confidence to both health care providers and patients,
Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over
6,000 hospitals worldwide. Elekta employs around 3,800 employees
globally. The corporate headquarters is located in Stockholm, Sweden,
and the company is listed on NASDAQ Stockholm. Website:
www.elekta.com.

-----------------------------------------------------------
http://news.cision.com/elekta/r/leeds-st-james-acquires-eight-elekta-lin...
http://mb.cision.com/Main/35/2010245/516488.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.